Status:
WITHDRAWN
Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients
Lead Sponsor:
Midwestern University
Conditions:
Renal Failure
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Ceftazidime is a broad spectrum cephalosporin with high activity against a variety of Gram-negative pathogens, including Pseudomonas aeruginosa. An open-label study of intravenous ceftazidime pharmaco...
Eligibility Criteria
Inclusion
- Eligible patients are male or female adults ≥18 years of age with an expected hospital stay of at least 48 hours, who have end-stage renal disease and been receiving intermittent hemodialysis for at least 90 days.
- Eligible patients will additionally have either central or peripheral intravenous access, and will already be prescribed ceftazidime per their primary providers.
- Written informed consent in a form approved by Northwestern Memorial Hospital, Northwestern University Institutional Review Board, and Midwestern University Institutional Review Board will be completed by the patient prior to enrollment.
Exclusion
- Patients that only receive one dose of ceftazidime in total
- Patients with potentially altered pharmacokinetic parameters (pregnant patients, burn patients, and those that are morbidly obese (BMI ≥ 40 kg/m2).
- Not meeting inclusion criteria
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01507532
Start Date
January 1 2012
End Date
January 1 2016
Last Update
March 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611